Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-06
2010-12-07
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S146000, C548S182000, C548S183000, C514S365000
Reexamination Certificate
active
07846953
ABSTRACT:
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
REFERENCES:
patent: 6518268 (2003-02-01), Chin et al.
patent: 7087576 (2006-08-01), Nag et al.
patent: 2006/0014812 (2006-01-01), Player et al.
patent: 0537300 (1995-04-01), None
patent: 1398029 (2004-03-01), None
patent: WO 2006/047269 (2006-05-01), None
Aranda et al., “Nuclear Hormone Receptors and Gene Expression.”, Physiol. Rev., 2001, vol. 81(3), pp. 1269-1304.
Ariazi et al., “Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer 1.”, Cancer Res., 2002, vol. 62, pp. 6510-6518.
Berge et al., “Pharmaceutical Salts.”, J. Pharm.Sci., 1977, vol. 66(1), pp. 1-19.
Bonnelye et al., “Estrogen Receptor-Related Receptor α Impinges on the Estrogen Axis in Bone: Potential Function in Osteoporosis.”, Endocrinology, 2002, vol. 143(9), pp. 3658-3670.
Bonnelye et al., “The ERR-1 Orphan Receptor Is a Transcriptional Activator Expressed During Bone Development.”, Mol. Endocrin, 1997, vol. 11, pp. 905-916.
Bonnelye et al., “The Orphan Nuclear Estrogen Receptor-related Receptor α (ERRα) Is Expressed throughout Osteoblast Differentiation and Regulates Bone Formation In Vitro.”, J. Cell Biol. 2001, vol. 153, pp. 971-984.
Giguere et al., “Identification of a new class of steroid hormone receptors.”, Nature 1988, vol. 331, pp. 91-94.
Giguere, V., “To ERR in the estrogen pathway.”, Trends in Endocrinol. Metab. 2002, vol. 13, pp. 220-225.
Giguerv, V., “Orphan Nuclear Receptors: From Gene to Function*.”, Endocrine Rev. 1999, vol. 20(5), pp. 689-725.
Gould, P.L., “Salt Selection for Basic Drugs.”, International J. Pharm., 1986, vol. 33, pp. 201-217.
Grundy et al., “Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition.”, Circulation 2004, vol. 109(3), pp. 433-438.
Hong et al., “Hormone-independent Transcriptional Activation and Coactivator Binding by Novel Orphan Nuclear Receptor ERR3*.”, J. Biol. Chem. 1999, vol. 274, pp. 22618-22626.
Jones, P.L. and Y.B. Shi, “N-CoR-HDAC Corepressor Complexes: Roles in Transcriptional Regulation by Nuclear Hormone Receptors.”, Curr. Top. Microbiol. Immunol., 2003, vol. 274, pp. 237-268.
Kamei et al., “PPARγ coactivator 1β ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity.”, Proc. Natl. Acad. Sci., USA , 2003, vol. 100(21), pp. 12378-12383.
Korach, K. S., “Insights from the Study of Animals Functional Estrogen Receptor.”, Science, 1994, vol. 266, pp. 1524-1527.
Kraus et al., “Estrogen-related Receptor α1 Actively Antagonizes Estrogen Receptor-regulated Transcription in MCF-7 Mammary Cells*.”, J. Biol. Chem. 2002, vol. 272, pp. 24826-24834.
Luo et al., “Reduced Fat Mass in Mice Lacking Orphan Nuclear Receptor Estrogen-Related Receptor α.”, Mol. Cell. Biol. 2003, vol. 23(22), pp. 7947-7956.
McKenna et al., “Nuclear Receptor Coregulators: Cellular and Molecular Biology.”, Endocrine Rev. 1999, vol. 20, pp. 321-344.
Olefsky, J.M., “Minireview Prologue. Nuclear Receptor Minireview Series*.”, J. Biol. Chem. 2001, vol. 276(40), pp. 36863-36864.
Pacifici, R.J., “Estrogen, Cytokines, and Pathogenesis of Postmenopausal Osteoporosis.”, Bone Miner. Res., 1996, vol. 11(8), pp. 1043-1051.
Rochette-Egly et al., “Retinoic Acid Receptor β: Immunodetection and Phosphorylation on Tyrosine Residues.”, Mol. Endocrinol., 1992, vol. 6, pp. 2197-2209.
Rochette-Egly et al., “Stimulation of RARa Activation Function AF-1 through Binding to the General Transcription Factor TFIIH and Phosphorylation by CDK7.”, Cell 1997, vol. 90, pp. 97-107.
Sladek et al., The Orphan Nuclear Receptor Estrogen-Related Receptor α Is a Transcriptional Regulator of the Human Medium-Chain Acyl Coenzyme A Dehydrogenase GeneMol. Cell. Biol. 1997, vol. 17, pp. 5400-5409.
Sumi, D. and L.J. Ignarro, “Estrogen-related receptor α1 up-regulates endothelial nitric oxide synthase expression.”, Proc Natl. Acad. Sci. 2003, vol. 100, pp. 14451-14456.
Turner et al., “Skeletal Effects of Estrogen.”, Endocrine Rev. 1994, vol. 15(3), 275-300.
Vanacker., “Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ.”, The EMBO Journal, 1999, vol. 18, pp. 4270-4279.
Vega, R.B. and D.P. Kelly, “A Role for Estrogen-related Receptor α in the Control of Mitochondrial Fatty Acid β-Oxidation during Brown Adipocyte Differentiation*.”, J. Biol. Chem. 1997, vol. 272, pp. 31693-31699.
Windahl et al., “Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ-/- mice.”, J. Clin. Invest., 1999, vol. 104(7), pp. 895-901.
Wurtz et al., “A canonical structure for ligand-binding domain of nuclear receptors.”, Nat. Struct. Biol.,1996, vol. 3, pp. 87-94.
Xu et al., “Structural basis for antagonistmediated recruitment of nuclear co-repressors by PPARa.”, Nature 2002, vol. 415 (6873), pp. 813-817.
Zhang, Z. and C.T. Teng, “Estrogen Receptor-related Receptor α1 Interacts with Coactivator and Constitutively Activates the Estrogen Response Elements of the Human Lactoferrin Gene*.”, J. Biol. Chem., 2000, vol. 275, pp. 20837-20846.
International Search Report, International Application No. PCT/US2008/056004, Date of Mailing of International Search Repont, Jul. 11, 2008.
Strum et al., “Rosiglitazone Induces Mitochondrial Biogenesis in Mouse Brain.”, Journal of Alzheimer's Disease, 2007, vol. 11(1), pp. 45-51, IOS Press, Asterdam, NL.
Gaul Michael
Kim Alexander
Patch Raymond
Rentzeperis Dionisois
Searle Lily Lee
Janssen Pharmaceutica NV
McKown Jeremy K.
Shameem Golam M
LandOfFree
Substituted phenoxy thiazolidinediones as estrogen related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted phenoxy thiazolidinediones as estrogen related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenoxy thiazolidinediones as estrogen related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190394